| Literature DB >> 31708538 |
Hiromichi Ohtsuka1, Masatomo Nakazono2, Takahiro Kondoh1, Hidetoshi Higuchi1, Motoshi Tajima1, Masateru Koiwa1.
Abstract
The immune related factors of peripheral blood mononuclear cells (PBMC) were analyzed in the clinical cases with Mycoplasma (M.) bovis infection. Seventy-eight Holstein calves in one farm were used. These calves were divided into three groups; the calves with M. bovis infection of poor outcome after treatment (Non-Recovery Group), the calves with M. bovis infection recovered (Recovery Group) and clinically healthy calves (Control Group). Blood samples were collected at days of the first medical treatment and the final treatment or euthanasia. IL-17A levels in the Non-Recovery Group were higher than those in the Recovery Group on both days. Our result suggested that the IL-17A of PBMC is an important factor to affect outcome of the calves with M. bovis infection.Entities:
Keywords: Mycoplasma bovis; calf; clinical case; immune factor; peripheral blood mononuclear cell
Mesh:
Substances:
Year: 2019 PMID: 31708538 PMCID: PMC6983659 DOI: 10.1292/jvms.19-0161
Source DB: PubMed Journal: J Vet Med Sci ISSN: 0916-7250 Impact factor: 1.267
Primers used for real-time PCR expression analysis
| Gene | Accession number | Product length | Primer designation | Sequence (5′-3′) |
|---|---|---|---|---|
| IL-2 | NM_180997.2 | 113 | Forward | AACCTCAACTCCTGCCACAAT |
| Reverse | TCATTGTGTTCCCCGTAGAGC | |||
| IL-4 | NM_173921 | 117 | Forward | GCCCCAAAGAACACAACTGA |
| Reverse | GAGATTCCTGTCAAGTCCGC | |||
| IL-12p40 | NM_174356.1 | 101 | Forward | CACCCCGCATTCCTACTTCT |
| Reverse | TGACTTTGGCTGAGGTTTGG | |||
| IL-17A | NM_001008412.2 | 138 | Forward | ATCTCACAGCGAGCACAAGT |
| Reverse | GTGGGATGATGACTCCTGCC | |||
| IL-17RA | XM_010827963.1 | 97 | Forward | TTCAGCAGCTGCCTCAACG |
| Reverse | GGGGCGTATGGTCTTCATTG | |||
| IL-21 | NM_198832.1 | 144 | Forward | CAGCTCCAGAAGATGTAAAGAGAC |
| Reverse | TGGCAGGTAGTTTCCTCTTCA | |||
| IFN-γ | NM_174086 | 108 | Forward | TCAAATTCCGGTGGATGATCT |
| Reverse | CTTCTCTTCCGCTTTCTGAGG | |||
| CCL3 | NM_174511.2 | 117 | Forward | CTGACGCTCAAGCCCACACT |
| Reverse | CGCCAAATGGTGCCGAGAAG | |||
| CCR5 | NM_001011672.2 | 90 | Forward | GGCTCCCTACAACATCGTCC |
| Reverse | GCTTGGTCCAGCCTGTTAGA | |||
| β-actin | NM_173979.3 | 76 | Forward | CCCAGATCATGTTCGAGACC |
| Reverse | GAGGCATACAGGGACAGCAC | |||
Cytokine mRNA expression of peripheral blood mononuclear cells in three groups
| Particle | Sampling day | Unfavorable group | Favorable group | Control group | |
|---|---|---|---|---|---|
| (N=13) | (N=51) | (N=14) | |||
| IL-2 | First | 3.20 ± 0.23 | 3.24 ± 0.18 | 4.54 ± 0.46 | |
| Last | 3.05 ± 0.31 | 2.86 ± 0.18 | |||
| IL-4 | First | 8.37 ± 0.48 | 8.24 ± 0.25 | 9.24 ± 0.57 | |
| Last | 7.20 ± 0.75 | 8.52 ± 0.22 | |||
| IL-12p40 | First | 5.25 ± 0.55 | 4.27 ± 0.26 | 5.21 ± 0.42 | |
| Last | 5.94 ± 0.59 | 4.60 ± 0.22 | |||
| IL-17A | First | 8.86 ± 0.79 a) | 7.52 ± 0.32 a) | * | 11.17 ± 0.43 b) |
| Last | 8.67 ± 0.25 a) | 7.49 ± 0.35 a) | * | ||
| IL-17R | First | 4.94 ± 0.32 | 4.37 ± 0.15 a) | 6.63 ± 0.46 b) | |
| Last | 5.11 ± 0.28 | 4.10 ± 0.13 a) | |||
| IL-21 | First | 7.26 ± 0.78 a) | 8.10 ± 0.24 | 9.53 ± 0.51 b) | |
| Last | 8.41 ± 0.36 | 7.91 ± 0.21 | |||
| IFN-γ | First | 10.32 ± 0.38 a) | 9.93 ± 0.27 a) | 13.15 ± 0.43 b) | |
| Last | 10.56 ± 0.61 a) | 9.80 ± 0.38 a) | |||
| CCL3 | First | 8.13 ± 0.57 | 6.75 ± 0.31 | 8.23 ± 0.40 | |
| Last | 8.23 ± 0.53 | 6.52 ± 0.28 | |||
| CCR5 | First | 5.09 ± 0.43 a) | 4.97 ± 0.21 a) | 7.84 ± 0.65 b) | |
| Last | 5.20 ± 0.49 a) | 4.94 ± 0.22 a) | |||
Data are expressed as the mean ± SE (target gene mRNA/β-actin gene mRNA). Values denote relative expression of each parameters mRNA. Different letters indicate significant difference among groups (P<0.05). P value means significant difference between two infected groups.